机构：[1]Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China神经科系统神经内科首都医科大学宣武医院
BackgroundIt remains unclear whether cerebrospinal fluid (CSF) VGF (non-acronymic) is associated with the onset and progression of Alzheimer's disease (AD).ObjectiveTo assess the levels of CSF VGF throughout the AD continuum, and its association with primary AD pathology, cognition, brain atrophy, and brain metabolism.MethodsWe studied a total of 526 individuals including 377 amyloid-positive individuals (76 preclinical AD, 200 prodromal AD, and 101 AD dementia) and 149 amyloid-negative cognitively normal individuals. VGF peptide in CSF was analyzed using mass spectrometry.ResultsWe observed decreased CSF VGF in preclinical, prodromal, and AD dementia individuals than amyloid-negative cognitively normal individuals. Reduced CSF VGF was associated with cognitive decline, hippocampal atrophy, ventricle enlargement, and glucose hypometabolism at baseline, and it predicted a more marked deterioration over time.ConclusionsOur findings support the important contributions of VGF to disease pathogenesis and progression in the early stages of AD. Exploring the biologics modulating VGF might be a promising approach for AD prevention and early treatment.
基金：
Data collection and sharing for the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) is funded by the National
Institute on Aging (National Institutes of Health Grant
U19AG024904) and DOD ADNI (Department of Defense award
number W81XWH-12-2-0012). The grantee organization is the
Northern California Institute for Research and Education. In the
past, ADNI has also received funding from the National Institute
of Biomedical Imaging and Bioengineering, the Canadian
Institutes of Health Research, and private sector contributions
through the Foundation for the National Institutes of Health
(FNIH) including generous contributions from the following:
AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery
Foundation; Araclon Biotech; BioClinica, Inc.; Biogen;
Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai
Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company;
EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated
company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd;
Janssen Alzheimer Immunotherapy Research & Development,
LLC.; Johnson & Johnson Pharmaceutical Research &
Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;
Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack
Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.;
Piramal Imaging; Servier; Takeda Pharmaceutical Company; and
Transition Therapeutics.
第一作者机构：[1]Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Lu Yuanyuan,Li Dan,Yu Yueyi,et al.Cerebrospinal fluid VGF is associated with the onset and progression of Alzheimer's disease[J].Journal Of Alzheimer's Disease : JAD.2025,104(4):1235-1242.doi:10.1177/13872877251323002.
APA：
Lu Yuanyuan,Li Dan,Yu Yueyi,Wang Qianqian,Li Aonan...&Xing Yi.(2025).Cerebrospinal fluid VGF is associated with the onset and progression of Alzheimer's disease.Journal Of Alzheimer's Disease : JAD,104,(4)
MLA：
Lu Yuanyuan,et al."Cerebrospinal fluid VGF is associated with the onset and progression of Alzheimer's disease".Journal Of Alzheimer's Disease : JAD 104..4(2025):1235-1242
